 |
市場調查報告書
呼吸系統的合作條件與契約Global Respiratory Partnering 2014-2019: Deal trends, players and financials |
||||||
| 出版商 | Current Partnering, a division of Wildwood Ventures Limited | 商品編碼 | 250310 | ||||
| 出版日期 | 內容資訊 | 英文 200+ Pages 商品交期: 最快1-2個工作天內 |
|||||
| 價格 |
|
||||||
| 呼吸系統的合作條件與契約 Global Respiratory Partnering 2014-2019: Deal trends, players and financials | ||
| 出版日期: 2019年09月01日 | 內容資訊: 英文 200+ Pages |
|
本報告提供呼吸系統的合作相關契約調查分析，全球依各主要醫療企業所簽訂的各種契約趨勢，主要交易，大規模相關交易檢驗，也包含不同市場區隔的契約名錄，為您概述為以下內容。
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
‘The Global Respiratory Partnering 2014-2019: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies.
‘Global Respiratory Partnering 2014 to 2019’ provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.
The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Respiratory dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Respiratory deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Respiratory deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2014. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.
‘Global Respiratory Partnering 2014 to 2019’ is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.
‘Global Respiratory Partnering 2014 to 2019’ includes:
The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestation, Snoring, Wheeze, plus other respiratory indications.
In ‘Global Respiratory Partnering 2014 to 2019’, available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
‘The Global Respiratory Partnering 2014-2019 report’ provides comprehensive access to available deals and contract documents for over 400 respiratory deals. Analyzing actual contract agreements allows assessment of the following:
